An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Vilazodone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Acronyms VLZ-MD-23
- Sponsors Allergan; Forest Laboratories
- 21 Feb 2018 Planned End Date changed from 1 Jan 2018 to 17 Jul 2018.
- 21 Feb 2018 Planned primary completion date changed from 1 Nov 2017 to 17 Jul 2018.
- 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.